Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F145 - Research Gaps in Psoriasis: Opportunities for Future Studies and Development of New Outcome Measures for Clinical Trials

Monday, February 19; 3:30 PM - 5:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Identify gaps in research and clinical knowledge
  • Suggest studies that can be conducted to fill the gaps
  • Discuss the development of new outcome measures in dermatology

Description

This session will be helpful in expanding physician knowledge base in the field of psoriasis. Despite important advances, substantial deficits remain in the understanding of psoriasis and its treatment, necessitating further research in many areas. In this session the most important gaps in research that exist currently and suggestions for studies that should be performed to address these deficits will be discussed. The session will also address the efforts of International Dermatology Outcomes Measures (IDEOM) Committee to develop outcome measures that accurately and reliably measure the impact of treatments on patients' disease severity and quality of life using the Delphi method.

Disclosures

  • Armstrong, April W., MD, MPH: AbbVie – C(H), SP(H); Boehringer Ingelheim – Data Safety Monitoring Board(H); Bristol-Myers Squibb – C(H); Celgene – I(Grants/Research Funding); Demira – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding), SP(H); Genzyme Corporation – C(H); GlaxoSmithKline – C(H); Janssen Pharmaceuticals, Inc – SP(H); Janssen-Ortho Inc. – I(Grants/Research Funding); Leo Pharma Inc – C(H), I(Grants/Research Funding); Menlo Therapeutics – C(H); Modernizing Medicine – C(H); Novartis Pharmaceuticals Corp. – A(H), I(Grants/Research Funding); Ortho Dermatologics – C(H); Pfizer Inc. – C(H); Regeneron – I(NC); Regeneron Pharmaceuticals, Inc. – SP(H); Sanofi – I(NC), SP(H); Science 37, Inc. – C(H); UCB – I(Grants/Research Funding);
  • Callis-Duffin, Kristina Patrice, MD: AbbVie – C(H), I(Grants/Research Funding), SP(H); Amgen – A(H), C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(Fees); Celgene Corporation – A(H), I(Grants/Research Funding); Eli Lilly and Company – C(H), I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H), I(Grants/Research Funding); Novartis – C(H), I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); Sienna Biopharmaceuticals – C(H), I(Grants/Research Funding); Stiefel a GSK company – I(Grants/Research Funding); Xenoport, Inc – I(Grants/Research Funding);
  • Gottlieb, Alice B., MD, PhD: AbbVie – C(H), SP(H); BMS – A(H); Celgene Corporation – A(H); Dermira – C(H); Eli Lilly and Company – SP(H); Incyte Corporation – C(H), I(Grants/Research Funding); Janssen Biotech – SP(H); Janssen-Ortho Inc. – A(H), I(Grants/Research Funding); LEO Pharma, US – A(H); Lilly ICOS LLC – C(H), I(Grants/Research Funding); Novartis – C(H), I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H); UCB – A(H), I(Grants/Research Funding); XBiotech – C(NC), I(Grants/Research Funding);
  • Lebwohl, Mark, MD: AbbVie – I(Grants/Research Funding); Allergan, Inc. – C(H); Aqua – C(H); Arcutis, Inc. – C(H); AstraZeneca – I(Grants/Research Funding); Boehringer Ingelheim – C(H); Bristol-Myers Squibb – C(H); Celgene Corporation – I(Grants/Research Funding); Corrona, Inc. – O(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Incyte Corporation – I(Grants/Research Funding); Janssen Research & Development, LLC – I(Grants/Research Funding); Leo Pharma Inc – C(H); Medimmune – I(Grants/Research Funding); Menlo Therapeutics – C(H); Mitsibushi Pharma – C(H); Neuroderm LTD – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); SCIderm – I(Grants/Research Funding); Theravance Biopharma – C(H); UCB – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding); Verrica Pharmaceuticals Inc – C(H); Vidac Pharma – I(Grants/Research Funding);
  • Marcus, Kendall, MD: no financial relationships exist with commercial interests.
  • Merola, Joseph, MD, MSc: AbbVie – A(H), SP(H); Biogen – C(Fees), I(Grants/Research Funding); Eli Lilly and Company – A(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H); Novartis – A(H); Pfizer Inc. – I(NC);
Schedule
Monday, February 19
3:30 PM
Dr. Gottlieb / Introduction
3:35 PM
Dr. Lebwohl / Key Research Gaps in Psoriasis and Psoriatic Arthritis
3:55 PM
Dr. Marcus / The Brodalumab Safety Review
4:15 PM
Dr. Callis-Duffin / Psoriasis Domains for Clinical Trials
4:35 PM
Dr. Gottlieb / The Use of Measures to Define Minimal Disease Activity for Psoriasis (PGA x BSA as a PASI Proxy)
4:55 PM
Dr. Armstrong / Treatment of Satisfaction Domain Outcome Measures
5:15 PM
Dr. Merola / Psoriatic Arthritis Symptoms Measures for Dermatology
Event Details
  • Date
    Monday, February 19
  • Time
    3:30 PM - 5:30 PM
  • Location
    Room 28A
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
  • Alice B. Gottlieb, MD, PhD, FAAD - Handout
Speakers
  • April W. Armstrong, MD, MPH, FAAD
  • Joseph Merola, MD, MSc, FAAD
  • Kendall Marcus, MD
  • Kristina Patrice Callis-Duffin, MD, FAAD
  • Mark Lebwohl, MD, FAAD - Handout